for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Natco Pharma Ltd.

NATP.NS

Latest Trade

575.20INR

Change

-2.00(-0.35%)

Volume

80,341

Today's Range

567.55

 - 

584.00

52 Week Range

480.00

 - 

799.90

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

Natco Pharma Raises Stake In OMRV Hospitals Pvt Ltd To 12.81%

Aug 23 (Reuters) - Natco Pharma Ltd <NATP.NS>::RAISES STAKE IN OMRV HOSPITALS PVT LTD TO 12.81% FROM 9.29%.

India's Natco Pharma June-Qtr Consol Net Profit Falls

Aug 9 (Reuters) - Natco Pharma Ltd <NATP.NS>::JUNE QUARTER CONSOL NET PROFIT 1.43 BILLION RUPEES VERSUS 1.82 BILLION RUPEES YEAR AGO.JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 4.92 BILLION RUPEES VERSUS 5.39 BILLION RUPEES YEAR AGO.

Natco Pharma Gets Establishment Inspection Report For Kothur Facility

Aug 5 (Reuters) - Natco Pharma Ltd <NATP.NS>::NATCO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR KOTHUR FACILITY.GETS EIR FROM USFDA FOR INSPECTION CONDUCTED AT KOTHUR DRUG FORMULATIONS FACILITY DURING MAY 30-JUNE 5.

Natco Pharma Settles Generic Carfilzomib Injection Patent Litigation In U.S. Market

May 30 (Reuters) - Natco Pharma Ltd <NATP.NS>::SAYS NATCO SETTLES GENERIC CARFILZOMIB INJECTION PATENT LITIGATION IN US MARKET.SAYS THE PARTIES HAVE REACHED A SETTLEMENT AGREEMENT AND THE DISTRICT COURT CASE HAS BEEN DISMISSED.NATCO, BRECKENRIDGE GRANTED LICENSE PERMITTING LAUNCH OF GENERIC CARFILZOMIB PRODUCT IN 2027 OR SOONER.

India's Natco Pharma March Quarter Consol Net Profit Falls

May 27 (Reuters) - Natco Pharma Ltd <NATP.NS>::MARCH QUARTER CONSOL NET PROFIT 1.2 BILLION RUPEES VERSUS 3 BILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 4.56 BILLION RUPEES VERSUS 7.68 BILLION RUPEES YEAR AGO.DECLARED THIRD INTERIM DIVIDEND OF 1.25 RUPEES PER SHARE.

Natco Pharma Gets ANDA Approval From USFDA For Bosentan Tablets

May 2 (Reuters) - Natco Pharma Ltd <NATP.NS>::GOT ANDA APPROVAL FROM USFDA FOR BOSENTAN TABLETS IN STRENGTHS OF 62.5 MG AND 125 MG.

Lupin In Alliance With Natco Pharma Gets FDA Approval For Bosentan Tablets

April 30 (Reuters) - Lupin Ltd <LUPN.NS>::LUPIN IN ALLIANCE WITH NATCO RECEIVES FDA APPROVAL FOR BOSENTAN TABLETS.

India's Natco Pharma Dec Qtr Consol Net Profit Falls

Feb 12 (Reuters) - Natco Pharma Ltd <NATP.NS>::DEC QUARTER CONSOL NET PROFIT 1.60 BILLION RUPEES VERSUS PROFIT 2.18 BILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 5.57 BILLION RUPEES VERSUS 5.62 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 3.50 RUPEES PER SHARE.

Natco Pharma Launches Valsartan/Sacubitril Tablet In India

Jan 28 (Reuters) - Natco Pharma Ltd <NATP.NS>::SAYS NATCO LAUNCHES VALSARTAN/SACUBITRIL TABLET IN INDIA.SAYS DRUG IS USED FOR CERTAIN TYPES OF HEART FAILURE.

Natco Pharma Initiates Greenfield Facilities For Niche Agrichemical Business

Jan 25 (Reuters) - Natco Pharma Ltd <NATP.NS>::SAYS NATCO INITIATES GREENFIELD FACILITIES FOR NICHE AGRICHEMICAL BUSINESS.SAYS FACILITIES WILL MANUFACTURE BOTH AGRICHEMICAL TECHNICAL AND FORMULATION PRODUCTS.EXPECTS FACILITIES TO BE COMMISSIONED BY END OF 2019 WITH A TOTAL CAPITAL EXPENDITURE OF 1 BILLION RUPEES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up